Trial Profile
Phase IIa trial to evaluate different delivery schedules of recombinant human interleukin-7 in combination with oral capecitabine in the second-line treatment of metastatic breast cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Interleukin-7 (Primary) ; Capecitabine
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms ELYPSE-7
- 26 Jun 2014 New source integrated into profile.
- 26 Jun 2014 Planned End Date changed to 1 Jun 2014.
- 26 Jun 2014 Planned primary completion date changed to 1 Sep 2013.